Segment reporting (Tables)
Jun. 30, 2026
Reportable segment | Principal activities |
Precision Medicine | Commercial sales of Illuccix, Gozellix and other diagnostic products subsequent to obtaining regulatory approvals. This segment includes the development activities of the Group’s diagnostic pipeline. The Group’s International and Medical Technologies businesses are operating segments that are included within the Precision Medicine reportable segment due to the similar nature of the diagnostic products being sold or developed for commercialization. |
Therapeutics | Developing the Group’s core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization, income from collaboration agreements and research and development services. This segment includes the development activities of the Group’s therapeutic pipeline. |
Manufacturing Solutions | This segment comprises revenues and costs associated with the Group's radiopharmacy network, other manufacturing facilities and assets associated with the Group’s vertically integrated manufacturing and supply chain. This business includes facilities at Brussels South, IsoTherapeutics, TMS Sacramento, North Melbourne, ARTMS and RLS Radiopharmacies. |
For the half-year ended | Precision Medicine | Therapeutics | Manufacturing Solutions | Inter- segment eliminations | Total segment | |||||
June 30, 2026 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | |||||
Revenue from contracts with customers | 388,633 | - | 88,717 | - | 477,350 | |||||
Inter-segment revenue | - | - | 57,543 | (57,543) | - | |||||
Cost of sales | (134,600) | - | (138,435) | 56,034 | (217,001) | |||||
Gross profit | 254,033 | - | 7,825 | (1,509) | 260,349 | |||||
Other income | - | 40,000 | - | - | 40,000 | |||||
Research and development costs | (54,482) | (67,968) | (2,828) | 1,450 | (123,828) | |||||
Selling and marketing expenses | (49,236) | - | (9,122) | - | (58,358) | |||||
Manufacturing and distribution costs | (6,625) | (2,348) | (19,740) | - | (28,713) | |||||
General and administration costs | (12,508) | (2,215) | (8,902) | - | (23,625) | |||||
Other gains/(losses) (net) | 1,195 | 1,240 | (176) | - | 2,259 | |||||
Operating profit/ (loss) | 132,377 | (31,291) | (32,943) | (59) | 68,084 | |||||
Other (gains)/losses (net) | (1,195) | (1,240) | 176 | - | (2,259) | |||||
Depreciation and amortization | 707 | 149 | 9,811 | - | 10,667 | |||||
Adjusted earnings/ (loss) before interest, tax, depreciation and amortization | 131,889 | (32,382) | (22,956) | (59) | 76,492 |
For the half-year ended | Precision Medicine | Therapeutics | Manufacturing Solutions | Inter-segment eliminations | Total segment | |||||
June 30, 2025 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | |||||
Revenue from contracts with customers | 305,835 | 3,994 | 80,530 | - | 390,359 | |||||
Inter-segment revenue | - | - | 33,761 | (33,761) | - | |||||
Cost of sales | (108,839) | (108) | (103,485) | 30,696 | (181,736) | |||||
Gross profit | 196,996 | 3,886 | 10,806 | (3,065) | 208,623 | |||||
Research and development costs | (38,116) | (43,868) | (2,664) | 3,065 | (81,583) | |||||
Selling and marketing expenses | (40,886) | (464) | (7,623) | - | (48,973) | |||||
Manufacturing and distribution costs | (4,105) | (1,710) | (13,034) | - | (18,849) | |||||
General and administration costs | (11,317) | (2,002) | (7,116) | - | (20,435) | |||||
Other (losses)/gains (net) | (1,593) | 19 | 27 | - | (1,547) | |||||
Operating profit/(loss) | 100,979 | (44,139) | (19,604) | - | 37,236 | |||||
Other losses/(gains) (net) | 1,593 | (19) | (27) | - | 1,547 | |||||
Depreciation and amortization | 2,074 | 117 | 6,969 | - | 9,160 | |||||
Adjusted earnings/(loss) before interest, tax, depreciation and amortization | 104,646 | (44,041) | (12,662) | - | 47,943 |
June 30 2026 | June 30 2025 | |||||
Note | US$'000 | US$'000 | ||||
Total segment adjusted EBITDA | 76,492 | 47,943 | ||||
Unallocated income, expenses and eliminations: | ||||||
General and administration costs | (25,038) | (27,288) | ||||
Other gains/(losses) (net) | 5,575 | (1,105) | ||||
Finance income | 2,274 | 3,616 | ||||
Finance costs | 4.5 | (19,388) | (18,842) | |||
Depreciation and amortization | 4.3 | (10,667) | (9,160) | |||
Profit/(loss) before income tax | 29,248 | (4,836) |
Precision Medicine | Therapeutics | Manufacturing Solutions | Total segment | Reconciling items | Group | |||||||
June 30, 2026 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | ||||||
Total assets | 323,308 | 232,997 | 523,819 | 1,080,124 | 281,727 | 1,361,851 | ||||||
Total liabilities | 157,343 | 25,828 | 141,994 | 325,165 | 549,011 | 874,176 | ||||||
Additions to non- current assets | 668 | 172 | 23,658 | 24,498 | — | 24,498 |
Precision Medicine | Therapeutics | Manufacturing Solutions | Total segment | Reconciling items | Group | |||||||
December 31, 2025 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | ||||||
Total assets | 233,252 | 228,110 | 515,429 | 976,791 | 187,195 | 1,163,986 | ||||||
Total liabilities | 159,523 | 17,099 | 156,599 | 333,221 | 415,389 | 748,610 | ||||||
Additions to non- current assets | 19,503 | 67,715 | 324,472 | 411,690 | 7,840 | 419,530 |
June 30, 2026 | June 30, 2025 | |||
Revenue by location of customer | Revenue by location of customer | |||
US$'000 | US$'000 | |||
United States | 468,074 | 381,051 | ||
Other countries | 9,276 | 9,308 | ||
Total | 477,350 | 390,359 |
June 30, 2026 | December 31, 2025 | ||
Non-current assets by location of asset | Non-current assets by location of asset | ||
US$'000 | US$'000 | ||
Australia | 110,383 | 101,753 | |
Belgium | 58,441 | 59,460 | |
Canada | 83,156 | 86,643 | |
United Kingdom | 39,146 | 37,071 | |
United States | 492,532 | 481,181 | |
Other countries | 4,877 | 8,245 | |
Total | 788,535 | 774,353 |